Discovery of a 2-pyridinyl urea-containing compound YD57 as a potent inhibitor of apoptosis signal-regulating kinase 1 (ASK1)

European Journal of Medicinal Chemistry
2020.0

Abstract

Inhibition of MAP3K kinase ASK1 has been an attractive strategy for the treatment of nonalcoholic steatohepatitis and multiple sclerosis, among others. Herein, we reported the discovery of 2-pyridinyl urea-containing compound 14l (YD57) as a potent, small-molecule inhibitor of ASK1. 14l was selective against MAP3K kinases ASK2 and TAK1 (>140-fold), while it also inhibited several cell cycle regulating kinases with IC values in a range of 90-400 nM (<20-fold selectivity). As a consequence, 14l had stronger apoptosis induction, more potent G1 cell cycle arrest activities, and lower IC value of cell growth inhibition than that of GS4997 in HepG2 cancer cell line. On the other hand, 14l did not inhibit ASK1 and p38 phosphorylation in intact cells. We reason that the multi-target effects of 14l likely neutralized the activities caused by inhibition of cellular ASK1. Future studies of these ASK1 inhibitors should pay close attention to their kinome selectivity profile.

Knowledge Graph

Similar Paper

Discovery of a 2-pyridinyl urea-containing compound YD57 as a potent inhibitor of apoptosis signal-regulating kinase 1 (ASK1)
European Journal of Medicinal Chemistry 2020.0
Identification of novel ASK1 inhibitors using virtual screening
Bioorganic &amp; Medicinal Chemistry 2011.0
Discovery of 2-arylquinazoline derivatives as a new class of ASK1 inhibitors
Bioorganic &amp; Medicinal Chemistry Letters 2018.0
Synthesis of new pyridazino[4,5-b]indol-4-ones and pyridazin-3(2H)-one analogs as DYRK1A inhibitors
Bioorganic &amp; Medicinal Chemistry Letters 2014.0
Discovery of a potent p38α/MAPK14 kinase inhibitor: Synthesis, in vitro/in vivo biological evaluation, and docking studies
European Journal of Medicinal Chemistry 2019.0
New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis
European Journal of Medicinal Chemistry 2019.0
Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors
Journal of Medicinal Chemistry 2021.0
Synthesis and structure–activity relationship of 3,4′-bispyridinylethylenes: Discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer
Bioorganic &amp; Medicinal Chemistry Letters 2006.0
1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors
Bioorganic &amp; Medicinal Chemistry Letters 2000.0
Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles and 1,3,5-trisubstituted pyrazoles as inhibitors of transforming growth factor β type 1 receptor (ALK5)
Bioorganic &amp; Medicinal Chemistry Letters 2009.0